Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration.

The development of biotech drugs such as peptides and proteins that act in the central nervous system has been significantly impeded by the difficulty of delivering them across the blood-brain barrier. The surface engineering of nanoparticles with lectins opened a novel pathway to the absorption of drugs loaded by biodegradable poly (ethylene glycol)-poly (lactic acid) nanoparticles in the brain following intranasal administration. In the present study, vasoactive intestinal peptide, a neuroprotective peptide, was efficiently incorporated into the poly (ethylene glycol)-poly (lactic acid) nanoparticles modified with wheat germ agglutinin and the biodistribution, brain uptake and neuroprotective effect of the formulation were assessed. The area under the concentration-time curve of intact 125I-vasoactive intestinal peptide in brain of mice following the intranasal administration of 125I-vasoactive intestinal peptide carried by nanoparticles and wheat germ agglutinin-conjugated ones was significantly enlarged by 3.5 approximately 4.7 folds and 5.6 approximately 7.7 folds, respectively, compared with that after intranasal application of 125I-vasoactive intestinal peptide solution. The same improvements in spatial memory in ethylcholine aziridium-treated rats were observed following intranasal administration of 25 microg/kg and 12.5 microg/kg of vasoactive intestinal peptide loaded by unmodified nanoparticles and wheat germ agglutinin-modified nanoparticles, respectively. Distribution profiles of wheat germ agglutinin-conjugated nanoparticles in the nasal cavity presented their higher affinity to the olfactory mucosa than to the respiratory one. Inhibition experiment with specific sugars suggested that the interaction between the nasal mucosa and the wheat germ agglutinin-functionalized nanoparticles were due to the immobilization of carbohydrate-binding pockets on the surface of the nanoparticles. The results clearly indicated wheat germ agglutinin-modified nanoparticles might serve as promising carriers especially for biotech drugs such as peptides and proteins.

[1]  J. Fahrenkrug Vasoactive intestinal polypeptide: measurement, distribution and putative neurotransmitter function. , 1979, Digestion.

[2]  I. Gozes,et al.  Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Gary M Pollack,et al.  Nasal drug administration: potential for targeted central nervous system delivery. , 2005, Journal of pharmaceutical sciences.

[4]  Tushar K. Vyas,et al.  Intranasal drug delivery for brain targeting. , 2005, Current drug delivery.

[5]  A D Roses,et al.  Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Mcculloch,et al.  Cerebral circulatory and metabolic effects of vasoactive intestinal polypeptide. , 1980, The American journal of physiology.

[7]  B. Jansson,et al.  The influence of gellan gum on the transfer of fluorescein dextran across rat nasal epithelium in vivo. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[8]  I. Kwon,et al.  In Vivo Gene Transfer to the Mouse Nasal Cavity Mucosa Using a Stable Cationic Lipid Emulsion , 2000, Molecules and cells.

[9]  V. Mutt,et al.  Polypeptide with Broad Biological Activity: Isolation from Small Intestine , 1970, Science.

[10]  M. Alonso,et al.  Stealth PLA-PEG Nanoparticles as Protein Carriers for Nasal Administration , 1998, Pharmaceutical Research.

[11]  A. Fisher,et al.  Choline analogs as potential tools in developing selective animal models of central cholinergic hypofunction. , 1980, Life sciences.

[12]  Xin-guo Jiang,et al.  Preparation, characterization and application of pyrene-loaded methoxy poly(ethylene glycol)–poly(lactic acid) copolymer nanoparticles , 2004 .

[13]  R. Thorne,et al.  Quantitative analysis of the olfactory pathway for drug delivery to the brain , 1995, Brain Research.

[14]  Maria José Alonso,et al.  Comparative Uptake Studies of Bioadhesive and Non-Bioadhesive Nanoparticles in Human Intestinal Cell Lines and Rats: The Effect of Mucus on Particle Adsorption and Transport , 2002, Pharmaceutical Research.

[15]  W. Frey,et al.  Delivery of Neurotrophic Factors to the Central Nervous System , 2001, Clinical pharmacokinetics.

[16]  M. Brewster,et al.  The use of human nasal in vitro cell systems during drug discovery and development. , 2005, Toxicology in vitro : an international journal published in association with BIBRA.

[17]  Wei Lu,et al.  Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration. , 2006, Biomaterials.

[18]  R. Prassl,et al.  Association of vasoactive intestinal peptide with polymer-grafted liposomes: structural aspects for pulmonary delivery. , 2007, Biochimica et biophysica acta.

[19]  W. Banks,et al.  Passage of vasoactive intestinal peptide across the blood–brain barrier , 2003, Peptides.

[20]  L. Helmuth Detangling Alzheimer's disease. New insights into the biological bases of the most common cause of dementia are pointing to better diagnostics and possible therapeutics. , 2003, Science of aging knowledge environment : SAGE KE.

[21]  A. Fisher,et al.  (±)-cis-2-Methyl-spiro(1,3-oxathiolane-5,3′) quinuclidine (AF102B): A new M1 agonist attenuates cognitive dysfunctions in AF64A-treated rats , 1989, Neuroscience Letters.

[22]  L. Jarrard,et al.  Behavioral and neurochemical effects of intraventricular AF64A administration in rats , 1984, Pharmacology Biochemistry and Behavior.

[23]  H. Natsume,et al.  Poly-L-Arginine Predominantly Increases the Paracellular Permeability of Hydrophilic Macromolecules Across Rabbit Nasal Epithelium in Vitro , 2003, Pharmaceutical Research.

[24]  V. Lelièvre,et al.  VIP as a cell-growth and differentiation neuromodulator role in neurodevelopment , 1995, Molecular Neurobiology.

[25]  C. Dong,et al.  Pharmacological profile of PMS777, a new AChE inhibitor with PAF antagonistic activity. , 2007, The international journal of neuropsychopharmacology.

[26]  J. Yuan,et al.  Estimation of variance for AUC in animal studies. , 1993, Journal of pharmaceutical sciences.

[27]  T. Getchell,et al.  Lectin histochemical localization of galactose, N-acetylgalactosamine, and N-acetylglucosamine in glycoconjugates of the rat vomeronasal organ, with comparison to the olfactory and septal mucosae , 1994, Cell and Tissue Research.

[28]  C. Lehr,et al.  Lectin-mediated drug targeting: history and applications. , 2004, Advanced drug delivery reviews.

[29]  Y. Rahman,et al.  Delivery of Nerve Growth Factor to the Brain via the Olfactory Pathway. , 1998, Journal of Alzheimer's disease : JAD.

[30]  H. Jacobsson,et al.  In vivo dynamical distribution of 131I-VIP in the rat studied by gamma-camera. , 1994, Nuclear medicine and biology.

[31]  D. Olton,et al.  Neurotrophic Strategies for Treating Alzheimer's Disease: Lessons from Basic Neurobiology and Animal Models a , 1993, Annals of the New York Academy of Sciences.

[32]  L. Illum Transport of drugs from the nasal cavity to the central nervous system. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[33]  W. Couet,et al.  Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats. , 2003, International journal of pharmaceutics.

[34]  A. Vila,et al.  Design of biodegradable particles for protein delivery. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[35]  G. Berger,et al.  Glycoconjugate Expression in Normal Human Inferior Turbinate Mucosa: A Lectin Histochemical Study , 2005, American journal of rhinology.

[36]  G. Glazner,et al.  VIP Neurotrophism in the Central Nervous System: Multiple Effectors and Identification of a Femtomolar‐Acting Neuroprotective Peptide , 1998, Annals of the New York Academy of Sciences.

[37]  J. Gobert,et al.  Behavioural and histological effects of low concentrations of intraventricular AF64A. , 1989, European journal of pharmacology.

[38]  D. Gurwitz,et al.  (+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3')quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's disease. , 1991, The Journal of pharmacology and experimental therapeutics.

[39]  F. Bloom,et al.  Vasoactive intestinal polypeptide induces glycogenolysis in mouse cortical slices: a possible regulatory mechanism for the local control of energy metabolism. , 1981, Proceedings of the National Academy of Sciences of the United States of America.